PillRx only · Tablet, Film Coated · Oral
Abacavir And Lamivudine
Abacavir Sulfate + Lamivudine
6 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
6 active makers
6 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$1.435
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
6
Active US suppliers
55%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
1.1K
Rx · 2026 Q1
38K
Units dispensed
-40%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it6 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Aurobindo Pharma Limited | unknown | 3 | SUPPLYING |
| Macleods Pharmaceuticals Limited | unknown | 3 | SUPPLYING |
| Laurus Labs Limited | unknown | 3 | SUPPLYING |
| Camber Pharmaceuticals, Inc. | unknown | 1 | SUPPLYING |
| Cipla USA Inc. | unknown | 1 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | unknown | 0 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.